Oyster Point Pharma to Present New Analyses at ARVO 2022

Oyster Point Pharma announced the presentation of data analyses at the Association for Research in Vision and Ophthalmology (ARVO) 2022, being held on May 1-4.

“We are pleased to be presenting new analyses of the pivotal trial data of Tyrvaya (varenicline solution) Nasal Spray for the treatment of the signs and symptoms of dry eye disease at ARVO, the premiere gathering for eye and vision scientists to share the latest research findings and collaborate on innovative solutions,” said Marian Macsai, MD, Chief Medical Officer, Oyster Point Pharma. “We’re committed to building knowledge around the efficacy and safety of Tyrvaya and its related outcomes for specific patient populations that were enrolled in the pivotal clinical trials.”

Details for the Oyster Point New Data Presentations are below:

Title: OC-01 (varenicline solution) Nasal Spray for the Treatment of Dry Eye Disease Signs and Symptoms in Subjects with Autoimmune Disease: Integrated Data from ONSET-1 and ONSET-2
Authors: Anat Galor, MD, MSPH, Andrea Gibson, PhD, Gretchen Blemker, OD, Laura Hendrix, MS
Date/Time: May 2, 2022, 12:30 PM to 2:30 PM MDT
Location: Colorado Convention Center, Exhibits Poster Hall

Title: PEARL Phase 2 Study of OC-02 Nasal Spray for the Treatment of Dry Eye Disease
Authors: Bennie Jeng, MD, Andrea Gibson, PhD, Puja Shah, OD, Laura Hendrix, MS
Date/Time: May 2, 2022, 12:30 PM to 2:30 PM MDT
Location: Colorado Convention Center, Exhibits Poster Hall

Title: Bilateral Effect of OC-01 Nasal Spray for Treatment of Dry Eye Disease Signs & Symptoms in Subjects with Mild, Moderate & Severe Dry Eye Disease
Authors: Laura M. Periman, MD, Sathi Maiti, OD, Alan G. Kabat, OD, FAAO, Laura Hendrix, MS Andrea Gibson, PhD
Date/Time: May 2, 2022, 12:30 PM to 2:30 PM MDT
Location: Colorado Convention Center, Exhibits Poster Hall